Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar User Fees: Industry, FDA Tussle On Ramp-Up Speed For Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Industry says performance goals should not be phased-in, but FDA says it does not have enough money to be full-strength at launch.
Advertisement

Related Content

Biosimilar User Fee Program Stresses FDA/Sponsor Meetings Early And Often
Biosimilar User Fee Agreement Includes “Financial Hold” On Development Programs For Failure To Pay
How Should FDA Collect The Biosimilar Product Development Fee?
How Should FDA Collect The Biosimilar Product Development Fee?
Generic User Fee Talks: Performance Metrics For Early Years Still Unresolved
Biosimilar User Fee Negotiations Under Way; Timetable Compressed
Biosimilar User Fee Negotiations Under Way; Timetable Compressed
Biosimilar User Fees Would Be Same As BLAs, Only Earlier
"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected

Topics

Advertisement
UsernamePublicRestriction

Register

PS072513

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel